22 Stocks Moving in Friday's Pre-Market Session
Gainers
Focus Universal Inc. (NASDAQ: FCUV) rose 42% to $15.24 in pre-market trading. The company’s shares jumped around 65% over the previous month.
vTv Therapeutics Inc. (NASDAQ: VTVT) rose 26.5% to $2.24 in pre-market trading after the company disclosed results of multiple ascending dose study and development plan for HPP737, an oral PDE4 inhibitor for the treatment of psoriasis.
Aehr Test Systems (NASDAQ: AEHR) rose 21.4% to $14.30 in pre-market trading after the company reported better-than-expected Q1 results. The company also said it sees FY21 revenue of $50 million.
Unique Fabricating, Inc. (NASDAQ: UFAB) rose 19.4% to $3.01 in pre-market trading. The company’s Director Patrick W Cavanagh acquired a total of 13333 shares at an average price of $2.25.
Progress Software Corporation (NASDAQ: PRGS) rose 15.3% to $53.30 in pre-market trading as the company reported better-than-expected results for its third quarter and raised FY21 guidance. The company also announced acquisition of privately held Kemp for $258 million in cash.
Minerva Neurosciences, Inc. (NASDAQ: NERV) rose 13.6% to $2.09 in pre-market trading after gaining around 10% on Thursday.
Borr Drilling Limited (NYSE: BORR) shares rose 8.1% to $0.7995 in pre-market trading after gaining around 4% on Thursday.
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) rose 7.3% to $2.06 in pre-market trading after declining around 8% on Thursday.
Argo Blockchain plc (NASDAQ: ARBK) rose 6.6% to $17.86 in pre-market trading. The company’s shares jumped around 12% on Thursday after the company priced its IPO at $15 per ADS.
Huaneng Power International, Inc. (NYSE: HNP) rose 6.3% to $23.30 in pre-market trading.
ReWalk Robotics Ltd.. (NASDAQ: RWLK) rose 5.5% to $2.29 in pre-market trading after jumping over 21% on Thursday.
ChemoCentryx, Inc. (NASDAQ: CCXI) rose 5.2% to $18.90 in pre-market trading after climbing around 5% in the previous session. ChemoCentryx, last month, reported a Q3 loss of $0.56 per share.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Check out these big penny stock gainers and losers
Losers
Helbiz, Inc. (NASDAQ: HLBZ) shares fell 12.1% to $20.21 in pre-market trading. Helbiz recently announced a partnership with Drover AI to integrate its PathPilot safety technology onto Helbiz e-scooters.
InnSuites Hospitality Trust (NYSE: IHT) fell 12.1% to $4.50 in pre-market trading after jumping over 45% on Thursday.
Four Seasons Education (Cayman) Inc. (NYSE: FEDU) fell 11.9% to $0.7310 in pre-market trading. Four Seasons Education shares climbed 43% on Thursday after the company announced board authorization to repurchase up to $15 million.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) shares fell 11% to $4.55 in pre-market trading after the company reported a proposed public offering of common stock.
MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) fell 9.8% to $11.54 in pre-market trading. MEDIROM Healthcare Technologies shares surged over 73% on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362 million.
Amplitude Healthcare Acquisition Corporation (NASDAQ: AMHC) shares fell 7.4% to $13.30 in pre-market trading after climbing over 40% on Thursday. The company announced shareholders approved the business combination with Jasper Therapeutics.
Senmiao Technology Limited (NASDAQ: AIHS) shares fell 7.4% to $0.7650 in pre-market trading after jumping over 16% on Thursday.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell 6.7% to $3.75 in pre-market trading. TransCode Therapeutics shares surged 53% on Thursday after the company announced that preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology.
Valneva SE (NASDAQ: VALN) fell 6.5% to $31.69 in pre-market trading. Valneva said it commenced recruitment of adolescents in its pivotal Phase 3 trial for its inactivated COVID-19 vaccine candidate VLA2001 in the U.K.
NIKE, Inc. (NYSE: NKE) fell 4.7% to $152.13 in pre-market trading. Nike reported better-than-expected earnings for its first quarter, while sales missed expectations. The company also lowered its sales forecast for the full year.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.